Skip to main content
Top

Breast Cancer Research and Treatment

Issue 2/1997

Content (11 Articles)

Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells

Rosella Silvestrini, Daniela Gornati, Nadia Zaffaroni, Alessandra Bearzatto, Cinzia De Marco

CeReS-18, a novel cell surface sialoglycopeptide, induces cell cycle arrest and apoptosis in a calcium-sensitive manner

Natalie A. Betz, Heideh K Fattaey, Brenda A. Westhoff, Avelina Q. Paulsen, Terry C. Johnson

Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma

Peter B. Vermeulen, Martha Libura, Jolantha Libura, Patrick J. O‘Neill, Peter van Dam, Eric Van Marck, Allan T. Van Oosterom, Luc Y. Dirix

Clinical significance of bcl-2 gene expression in human breast cancer tissues

Shunzo Kobayashi, Hirotaka Iwase, Yukashi Ito, Hiroko Yamashita, Hiroji Iwata, Toshinari Yamashita, Kazuko Ito, Tatsuya Toyama, Takaaki Nakamura, Akira Masaoka

Phase II study of vinorelbine and ifosfamide in anthtracycline resistent metastatic breast cancer

P. Pronzato, P. Queirolo, M. Landucci, F. Vaira, A. Vigani, M. Gipponi, F. Cafiero

Seasonal trends in the self-detection of breast cancer: indications from the Cancer and Steroid Hormone (CASH) study

Julie A. Ross, Richard K. Severson, Scott Davis, Janet L. Stanford, John D. Potter

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine